Tokyo-based biotechnology investment manager and venture incubator within the Remiges Ventures group. It sources early therapeutic discoveries from Japanese universities, research institutions and pharmaceutical companies, validates and translates them into drug-development programs, and builds companies around the resulting intellectual property. RDiscovery combines seed and early-stage financing with in-house scientific and clinical expertise, company formation, management support, board governance and subsequent syndicated fundraising. Its RDiscovery Fund supports pre-startup translational research as well as biotechnology ventures in Japan and internationally, connecting Japanese drug-discovery assets to global development networks. The Japanese manager is RDiscovery, KK, formerly Remiges Ventures, KK; it is distinct from the US parent Remiges Ventures.
Founded
—
Type
Venture capital
Funds1
RDiscovery Fund, LP$100M
Drug-discovery incubation fund managed by RDiscovery, KK, announced in April 2025 and reaching $100 million at an additional close announced May 28, 2026. It finances scientific discoveries before company formation, seed-stage intellectual-property creation, translational validation, and the establishment and growth of biotechnology companies. The fund connects Japanese academic and pharmaceutical research with global drug development and also invests in early-stage opportunities internationally. Named LPs include Japan Investment Corporation, ClavystBio, Shin Nippon Biomedical Laboratories, FUJIFILM, Senju Pharmaceutical, Toray, 1Globe Health and Okinawa regional partners including Okinawa Electric, Bank of the Ryukyus, Bank of Okinawa, Okinawa Kaiho Bank, Ryuseki, Kokuba-Gumi and Okinawa Cellular. This is the same vehicle launched in April 2025; the additional close is not explicitly described as final.